See more : Anuh Pharma Limited (ANUHPHR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of ScripsAmerica, Inc. (SCRCQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ScripsAmerica, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- China Nonferrous Metal Industry’s Foreign Engineering and Construction Co.,Ltd. (000758.SZ) Income Statement Analysis – Financial Results
- Shenzhen Phoenix Telecom Technology Co.,Ltd. (301191.SZ) Income Statement Analysis – Financial Results
- Andretti Acquisition Corp. (WNNR) Income Statement Analysis – Financial Results
- AMOREPACIFIC Group (002795.KS) Income Statement Analysis – Financial Results
- DexCom, Inc. (DXCM) Income Statement Analysis – Financial Results
ScripsAmerica, Inc. (SCRCQ)
About ScripsAmerica, Inc.
ScripsAmerica, Inc. develops and sells non-sterile topical and transdermal pain creams. The company also provides pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies. In addition, it distributes pharmaceutical products to independent pharmacies and other medical providers. The company was founded in 2008 and is based in Clifton, New Jersey. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2016.
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Revenue | 30.85M | 556.19K | 3.92M | 5.96M | 3.22M |
| Cost of Revenue | 3.26M | 496.09K | 3.38M | 4.47M | 2.54M |
| Gross Profit | 27.60M | 60.10K | 530.85K | 1.48M | 677.40K |
| Gross Profit Ratio | 89.44% | 10.81% | 13.56% | 24.90% | 21.03% |
| Research & Development | 0.00 | 0.00 | 37.52K | 595.17K | 267.34K |
| General & Administrative | 4.21M | 2.17M | 0.00 | 0.00 | 93.57K |
| Selling & Marketing | 27.53M | 259.11K | 0.00 | 0.00 | 0.00 |
| SG&A | 31.73M | 6.22M | 2.04M | 1.01M | 93.57K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.40M | 7.35M | 2.08M | 1.61M | 360.90K |
| Cost & Expenses | 34.66M | 7.85M | 5.46M | 6.08M | 2.90M |
| Interest Income | 134.90K | 0.00 | 0.00 | 1.27K | 1.69K |
| Interest Expense | 311.18K | 1.30M | 225.25K | 255.50K | 130.91K |
| Depreciation & Amortization | 21.75K | 1.96K | 0.00 | 1.27K | 1.69K |
| EBITDA | -3.95M | -9.12M | -1.55M | -125.65K | 318.19K |
| EBITDA Ratio | -13.32% | -1,311.02% | -39.48% | -2.11% | 9.88% |
| Operating Income | -3.81M | -7.29M | -1.55M | -126.92K | 316.50K |
| Operating Income Ratio | -12.34% | -1,311.37% | -39.48% | -2.13% | 9.83% |
| Total Other Income/Expenses | -940.16K | -3.92M | -272.83K | -254.24K | -129.21K |
| Income Before Tax | -4.75M | -11.21M | -1.82M | -381.16K | 187.29K |
| Income Before Tax Ratio | -15.39% | -2,016.11% | -46.45% | -6.40% | 5.81% |
| Income Tax Expense | 296.07K | 1.29M | 43.18K | -41.20K | 60.22K |
| Net Income | -4.73M | -11.20M | -1.86M | -339.96K | 127.07K |
| Net Income Ratio | -15.33% | -2,012.82% | -47.55% | -5.71% | 3.94% |
| EPS | -0.04 | -0.16 | -0.03 | -0.01 | 0.00 |
| EPS Diluted | -0.04 | -0.16 | -0.03 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 127.41M | 68.12M | 55.14M | 49.96M | 79.20M |
| Weighted Avg Shares Out (Dil) | 127.41M | 68.12M | 55.14M | 49.96M | 80.64M |
Source: https://incomestatements.info
Category: Stock Reports